WTO Decision On Access To COVID-19 Vaccines: A Waiver In Name Only?
Agreement Could Be Extended To Medicines And Diagnostics In Six Months
Executive Summary
R&D-based companies have denounced what they see as a dangerous and unjustified attack on intellectual property after the World Trade Organization’s ministerial conference finally adopted a decision on an IP waiver for COVID-19 vaccines. NGOs, by contrast, say the decision amounts to little more than a limited exception to existing rules on the compulsory licensing of medicines.
You may also be interested in...
UK Must Act Now To Reverse Decline In Life Sciences Sector
A new industry report has painted a sobering picture of the UK life sciences sector, which is facing challenges on a number of fronts including clinical research, market access and manufacturing. On the bright side, the report says that implementing the measures in the government’s Life Sciences Vision could make the UK a “world-leading” hub for drug discovery and development.
EU Targets Generics, Inspection Shortfalls & Environmental Assessments
As the European Commission prepares to publish its proposals for overhauling the EU pharmaceutical legislation at the end of the year, member states have been discussing a range of technical and legal issues such as the scope of the centralized approval procedure, the use of electronic product information and the shortage of inspection capacities.
EMA Reviewing Bavarian Nordic’s Imvanex For Vaccination Against Monkeypox
EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.